Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2006

View Archived Issues

EvoGenix enters technology collaboration agreement with CSL

Confirmatory U.S. phase III study for Sanvar

Partnership to test encapsulated human islets in phase I/II trial

Treatment begins in phase III study of Dyloject for postoperative pain

Cangene awarded U.S. Government contract for botulinum toxin immune globulin

Preclinical atria-selective protective action of RSD-1235 and phase III clinical data to date

Initial increase in vision from baseline with monthly dosing of Lucentis

NDA route planned for Xyotax for women with lung cancer

Fast track designation for talabostat in stage IIIB/IV NSCLC

Positive animal findings for antiinflammatory compound 1-TDC

Treatment begins in phase I/II study of Elacyt in leukemia

New study of tesmilifene with Taxotere in metastatic breast cancer

American Gastroenterological Association recommends Entocort EC

Ostabolin-C demonstrates effects on bone in rats

Therapeutic potential of AAE-581 seen in postmenopausal women

Targeting FKBP38 for neuroprotection

Recent patents report novel analgesic agents

Novel agents for treating neurological disorders disclosed in recent patent literature

Recent patents claim new therapeutic agents for psychological disorders

MabThera recommended for European approval for rheumatoid arthritis

Priority review for Gestiva NDA

Tibolone NDA deemed not approvable

FDA approves reintroduction of Tysabri

ATryn recommended for approval in Europe

Discovery Labs to withdraw Surfaxin MAA

Orally active Met inhibitor shows potential in renal cell carcinoma

Preliminary findings for ImClone's IMC-1121B in advanced cancer

Eltrombopag safe and effective in increasing platelet counts in humans

E-7389, a novel antitubulin agent with potential in breast and lung cancer

Good safety and evidence of antitumor activity described for TSU-68

CXCL7-derived peptide improves bone density and strength in preclinical studies

The CCR1 antagonist BX-471 evaluated in phase II clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.